Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC
The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL
Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.
Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center
Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.
Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care
Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.
